announced after the bell Monday that the FDA has requested additional information from the existing eteplirsen dataset to inform a decision on the acceptability of this dataset for a New Drug Application filing under the Subpart H Accelerated Approval regulatory pathway.
Sarepta Therapeutics gapped open sharply lower Tuesday, but traded in a range throughout the session. Shares finished down by 5.25 at $33.99, with volume at a 6-month high. The stock fell to nearly a 2-week low.
For comments and feedback: editorial@rttnews.com